0NIQ Stock Overview
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Sartorius Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €219.50 |
52 Week High | €310.50 |
52 Week Low | €178.60 |
Beta | 0.84 |
1 Month Change | -20.17% |
3 Month Change | -19.44% |
1 Year Change | -23.47% |
3 Year Change | -45.13% |
5 Year Change | 47.32% |
Change since IPO | 3,289.96% |
Recent News & Updates
Recent updates
Shareholder Returns
0NIQ | GB Life Sciences | GB Market | |
---|---|---|---|
7D | -3.9% | -4.6% | 1.2% |
1Y | -23.5% | -45.7% | 2.3% |
Return vs Industry: 0NIQ exceeded the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: 0NIQ underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
0NIQ volatility | |
---|---|
0NIQ Average Weekly Movement | 6.5% |
Life Sciences Industry Average Movement | 5.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0NIQ's share price has been volatile over the past 3 months.
Volatility Over Time: 0NIQ's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1870 | 14,614 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products.
Sartorius Aktiengesellschaft Fundamentals Summary
0NIQ fundamental statistics | |
---|---|
Market cap | €17.35b |
Earnings (TTM) | €148.80m |
Revenue (TTM) | €3.31b |
131.0x
P/E Ratio5.9x
P/S RatioIs 0NIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0NIQ income statement (TTM) | |
---|---|
Revenue | €3.31b |
Cost of Revenue | €1.80b |
Gross Profit | €1.51b |
Other Expenses | €1.36b |
Earnings | €148.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 19, 2024
Earnings per share (EPS) | 2.16 |
Gross Margin | 45.55% |
Net Profit Margin | 4.49% |
Debt/Equity Ratio | 134.4% |
How did 0NIQ perform over the long term?
See historical performance and comparison